Natco Pharma Share Price Target 2025, 2026, 2030, 2040, 2050
Natco Pharma Limited is a pharmaceutical company in India that focuses on research and development. The company makes and sells medicines for specific health conditions. It mainly targets smaller markets and provides solutions for tough medical problems. It has nine factories in India and two research centres in Telangana. It has two main areas of business: Pharmaceuticals and Agrochemicals. In Pharmaceuticals, the company makes and sells bulk drugs, finished medicines, and related services. In Agrochemicals, it makes and sells chemicals for farming. The company also makes key ingredients used in its medicines and sells them to countries like Brazil, Europe, and the USA.
- 1 What is Natco Pharma Ltd NSE: NATCOPHARM ?
- 2 Share price Target Tomorrow
- 3 Natco Pharma share price Target 2025
- 4 Natco Pharma share price Target 2026
- 5 Share price Target 2027
- 6 Share price Target 2028
- 7 Share price Target 2029
- 8 Natco Pharma share price Target 2030
- 9 Share price Target 2040
- 10 Share price Target 2050
- 11 Should I buy Natco Pharma stock?
- 12 Natco Pharma earning results
- 13 Is Natco Pharma stock good to buy? (Bull case & bear case)
- 14 Conclusion
- 15 FAQs
What is Natco Pharma Ltd NSE: NATCOPHARM ?
Natco Pharma Ltd was started in 1981 and is located in Hyderabad, India. It was founded by Dr. Arvind Kumar, and the company is well-known for making both generic and branded medicines. It makes high-quality medicines, especially for treating cancer, HIV, and other long-term health problems. The company operates in many countries around the world, not just in India. It focuses a lot on research and development, which helps it create new medicines and improve the ones it already makes. The company has modern factories that follow strict rules to make sure their medicines are safe and effective. Its goal is to provide affordable healthcare, which has helped it become an important company in both India and many other countries.
After reaching all-time high points. The stock is falling continuously. At the monthly time frame, a strong bearish candle formed. So in the short term, you should wait for the trend reversal and also with multiple confirmations for buying opportunities.
| Day | Minimum Price (Rs) | Maximum Price (Rs) |
| Tomorrow | -47 | +70 |
It is a pharmaceutical company that focuses on making and selling medicines for both local and international markets. The company sells its products in several countries and specializes in certain medical areas. Its active ingredients are mainly sold in places like Brazil, Europe, and the USA. Recently, the company has seen a significant increase in profit, and its operating profits have been going up. The company’s share price is expected to grow in the future. In 2025, its share price target would be ₹1618, as per our analysis.
As per our prediction, its share price will be between ₹600 and ₹1618 in 2025.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2025 | 600 | 1618 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 1110 | 1420 |
| February | 757 | 1341 |
| March | 708 | 1350 |
| April | 656 | 1368 |
| May | 600 | 1358 |
| June | 678 | 1369 |
| July | 780 | 1380 |
| August | 874 | 1400 |
| September | 988 | 1425 |
| October | 1125 | 1458 |
| November | 1258 | 1511 |
| December | 1358 | 1618 |
It has several facilities, including ones for making finished medicines, producing active pharmaceutical ingredients, creating crop health products, and conducting research. One of the company’s main focuses is Generic Research, where they work on using smart and affordable technology along with new ways to deliver medicines. Over time, the company’s sales have grown, and its total sales amount has also gone up. In 2026, its share price target would be ₹2473 as per our prediction.
Its share price would be between ₹964 to ₹2473 in 2026, as per our analysis.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2026 | 964 | 2473 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 1618 | 1945 |
| February | 1354 | 1548 |
| March | 1125 | 1287 |
| April | 964 | 1121 |
| May | 1059 | 1254 |
| June | 1144 | 1548 |
| July | 1354 | 1641 |
| August | 1484 | 1745 |
| September | 1669 | 2044 |
| October | 1941 | 2241 |
| November | 2145 | 2357 |
| December | 2290 | 2473 |
It has developed new drugs in the Oncology department and made them available worldwide. The company is well established in Canada with many new products in Oncology, anti-viral, cardiovascular, and CNS treatments. In the most recent financial year, the company earned a good amount of money from Canada. For research purposes, the company spent a lot of money on research and development, but this amount has been decreasing over time. The Return on Equity percentage for Natco Pharma was good over the past 5 years, then dropped in the last 3 years, but went up again in the last year. Similarly, the Return on Capital Employed percentage was strong in the last 5 years, then went down in the last 3 years, and increased again in the last year. In 2027, its share price target would be ₹3039 as per our analysis.
As per our prediction, its share price would be between ₹1524 to ₹3039 in 2027.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2027 | 1524 | 3039 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 2290 | 2490 |
| February | 1842 | 2041 |
| March | 1524 | 1754 |
| April | 1647 | 1982 |
| May | 1785 | 2154 |
| June | 1954 | 2265 |
| July | 2145 | 2351 |
| August | 2274 | 2474 |
| September | 2365 | 2584 |
| October | 2458 | 2754 |
| November | 2578 | 2954 |
| December | 2854 | 3039 |
Its Cardiology and Diabetology department also launched many new products like Ticagrelor, Vidanat, and Dabigatran, which were mainly used during the COVID-19 pandemic. The company also started doing business in Brazil and earned good money there. As it grew its business outside India, the number of foreign investors in the company increased, which is a good sign for its future. The company is old and has strong support from its promoters, which means many investors want to buy shares in the company. In 2028, its share price target would be ₹3727 as per our prediction.
Its share price would be between ₹2854 to ₹3727 in 2028, as per our analysis.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2028 | 2854 | 3727 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 2854 | 3080 |
| February | 2954 | 3145 |
| March | 3021 | 3178 |
| April | 3125 | 3225 |
| May | 3187 | 3268 |
| June | 3242 | 3365 |
| July | 3347 | 3378 |
| August | 3354 | 3458 |
| September | 3390 | 3494 |
| October | 3452 | 3545 |
| November | 3490 | 3690 |
| December | 3587 | 3727 |
The company mainly focuses on specific medical areas and complex products. It sells its products in over 40 countries, including the United States, India, Europe, and other regions. Its API products are mostly used in its products but are also sold to customers in countries like Brazil, Europe, and the USA. In the API area, It can create and make products using special techniques like multi-step synthesis, semi-synthetic fusion, high-potency APIs, and peptides. It also works in contract manufacturing, where it makes and supplies products for other pharmaceutical companies. In 2029, its share price target would be ₹4357 as per our analysis.
As per our prediction, its share price would be between ₹3587 to ₹4357 in 2029.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2029 | 3587 | 4357 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 3587 | 3787 |
| February | 3645 | 3821 |
| March | 3754 | 3856 |
| April | 3784 | 3887 |
| May | 3826 | 3925 |
| June | 3878 | 4021 |
| July | 3954 | 4087 |
| August | 4053 | 4121 |
| September | 4078 | 4156 |
| October | 4120 | 4225 |
| November | 4156 | 4280 |
| December | 4243 | 4357 |
The company became a public limited company, and a new certificate of incorporation was issued by the RoC Andhra Pradesh. The company opened a facility for manufacturing Parenterals at Nagarjuna Sagar, Telangana. It also started its chemical division at Mekaguda, Telangana. Natco Parenterals Limited, Natco Laboratories Limited, and Dr. Karanth Pharma Labs Private Limited combined with Natco Pharma. Later, Natco Pharma opened the Natco Research Center (NRC) at Sanathnagar, Hyderabad. In 2030, its share price target would be ₹5055 as per our prediction.
Its share price would be between ₹3512 to ₹5055 in 2030, as per our analysis.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2030 | 3512 | 5055 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 4243 | 4390 |
| February | 3841 | 4025 |
| March | 3652 | 3755 |
| April | 3512 | 3858 |
| May | 3756 | 3954 |
| June | 3867 | 4051 |
| July | 3957 | 4151 |
| August | 4057 | 4284 |
| September | 4157 | 4358 |
| October | 4254 | 4658 |
| November | 4547 | 4984 |
| December | 4851 | 5055 |
It introduced its first abbreviated new drug application (ANDA) in the United States. The company bought Savemart Pharmacy in the United States. It made its first Paragraph IV filing in the US. The company reached an important achievement in its earnings. Natco Pharma and Levomed LLC USA started a joint venture called Natcofarma Do Brasil to sell and distribute products in Brazil.
It became the first company to get a compulsory license from Bayer for its cancer drug, Nexavar, in India. The company set up a fully owned subsidiary called Natco Pharma Asia Pte Ltd to manage sales and distribution in Singapore. It also started a subsidiary, in Canada, to sell and distribute in Canada. In 2040, its share price target would be ₹10135 as per our analysis.
As per our prediction, its share price would be between ₹8351 to ₹10135 in 2040.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2040 | 8351 | 10135 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 8351 | 8564 |
| February | 8458 | 8689 |
| March | 8564 | 8874 |
| April | 8684 | 8978 |
| May | 8874 | 9084 |
| June | 8969 | 9154 |
| July | 9078 | 9254 |
| August | 9154 | 9357 |
| September | 9256 | 9548 |
| October | 9454 | 9684 |
| November | 9568 | 9984 |
| December | 9879 | 10135 |
It started a branch, in Australia, to sell and distribute products in Australia. The company introduced the first generic version of sofosbuvir in Nepal. Sofosbuvir is a medicine for chronic hepatitis C, originally sold by Gilead Sciences Inc. under the name Sovaldi. It became the first company in India to get approval for generic sofosbuvir tablets (400mg) from the Drugs Controller General of India. The generic version is sold under the name HEPCINAT, with the help of partners in India. The Board of Directors also agreed to sell its Save Mart Pharmacy Store in the USA to CARE MART Inc. In 2050, its share price target would be ₹17457 as per our prediction.
Its share price would be between ₹15000 to ₹17457 in 2050, as per our analysis.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2050 | 15000 | 17457 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 15000 | 15325 |
| February | 15241 | 15458 |
| March | 15354 | 15684 |
| April | 15451 | 15841 |
| May | 15754 | 16241 |
| June | 16058 | 16354 |
| July | 16154 | 16548 |
| August | 16254 | 16684 |
| September | 16441 | 16784 |
| October | 16574 | 16924 |
| November | 16844 | 17254 |
| December | 17121 | 17457 |
Should I buy Natco Pharma stock?
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2025 | 600 | 1618 |
| 2026 | 964 | 2473 |
| 2027 | 1524 | 3039 |
| 2028 | 2854 | 3727 |
| 2029 | 3587 | 4357 |
| 2030 | 3512 | 5055 |
| 2040 | 8351 | 10135 |
| 2050 | 15000 | 17457 |
It could be a good choice for long-term investment because it focuses on developing new medicines and has a variety of products in both healthcare and farming. The company is growing in countries like the USA, Europe, and Brazil, and its profits are increasing. But also, there are some risks, like the stock price going down recently, and the pharmaceutical industry can be unpredictable due to rules and competition. If you’re looking for short-term gains, it might be better to wait for the stock to recover. But if you’re planning to invest for a long time, It seems like a solid option. Just make sure it fits with your investment goals and is comfortable with risk.
Natco Pharma earning results
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
| Sales + | 1,915 | 2,052 | 1,945 | 2,707 | 3,999 |
| Expenses + | 1,332 | 1,446 | 1,681 | 1,772 | 2,245 |
| Operating Profit | 583 | 606 | 264 | 936 | 1,754 |
| OPM % | 30% | 30% | 14% | 35% | 44% |
| Other Income + | 107 | 104 | 99 | 105 | 126 |
| Interest | 22 | 13 | 18 | 14 | 19 |
| Depreciation | 100 | 117 | 143 | 164 | 187 |
| Profit before tax | 569 | 580 | 202 | 862 | 1,674 |
| Tax % | 19% | 24% | 16% | 17% | 17% |
| Net Profit + | 458 | 442 | 170 | 715 | 1,388 |
| EPS in Rs | 25.31 | 24.18 | 9.31 | 39.18 | 77.51 |
| Dividend Payout % | 27% | 22% | 48% | 14% | 12% |
Key Metrics
| TTM PE Ratio | PB Ratio | Dividend Yield | Sector PE | Sector PB | Sector Div Yld |
| 7.89 | 2.52 | 1.16% | 46.77 | 5.98 | 0.57% |
Peers & Comparison
| Stock | PE Ratio | PB Ratio | Dividend Yield |
| Natco Pharma Ltd | 10.60 | 2.52 | 1.16% |
| Sun Pharmaceutical Industries Ltd | 40.43 | 5.77 | 0.84% |
| Cipla Ltd | 28.67 | 4.41 | 0.89% |
| Torrent Pharmaceuticals Ltd | 61.93 | 14.96 | 0.92% |
Is Natco Pharma stock good to buy? (Bull case & bear case)
Bull Case:
- It has very little debt, which makes it financially stable and lowers risk for investors.
- The company maintains a strong dividend payout of 24.9%, which is good for investors looking for regular income.
- The company has good profit margins and uses its money efficiently, which indicates a well-run business.
- It has a strong presence in the U.S., especially in the oncology (cancer treatment) market, which is growing.
Bear Case:
- The company’s profit dropped by 37% recently, which could signal financial trouble shortly.
- The stock has been volatile, with big drops after bad earnings reports, which can be risky for investors.
Conclusion
It has good chances for growth in the long run, with its share price expected to go up in the future, due to its strong business in places like the U.S. and Brazil. The company is financially healthy, with low debt, good profits, and steady dividend payments. However, its stock has been unstable lately, with some drops because of weaker earnings, which could be risky for short-term investors. While It seems like a good choice for long-term investment, short-term investors may want to wait for the stock to improve before buying.
